Research on the FM3A murine tumor model demonstrated that while irinotecan initially caused a temporary reduction in peripheral blood lymphocytes, its combination with anti-PD-L1 therapy produced significantly greater antitumor effects than either agent alone. This evidence concerns the gene CD274 and neoplasm.